

Disclaimer: This document is an English translation of the original document in Japanese and has been prepared solely for reference purposes. In the event of any discrepancy between this English translation and the original in Japanese, the original shall prevail in all respects.



July 29, 2025

To whom it may concern:

Company name KISSEI PHARMACEUTICAL CO., LTD.  
Representative Mutsuo Kanzawa, Chairman and CEO  
(Stock code 4547; Prime Market, Tokyo  
Stock Exchange)  
Contact Takahide Kitahara, Managing Director,  
Department Manager of Corporate Finance  
and Management Department, CFO  
(Telephone +81-263-25-9081)

# Notice Concerning Revisions to Financial Results Forecast and Recording of Extraordinary Income

In light of the recent trends in financial results and other factors, KISSEI PHARMACEUTICAL CO., LTD. (the “Company”) hereby announces that it has revised the financial results forecast for the six months ending September 30, 2025 and the fiscal year ending March 31, 2026 announced on May 7, 2025 as follows. The Company also announces that it expects to record extraordinary income from the sale of a portion of its investment securities holdings.

## 1. Revisions to the Financial Results Forecast

### (1) Revisions to the Consolidated Financial Results Forecast Figures for the Six Months Ending September 30, 2025 (April 1, 2025 – September 30, 2025)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Basic earnings per share
Previously announced forecast (A)	Million yen 44,300	Million yen 2,300	Million yen 3,100	Million yen 6,200	Yen 149.74
Revised forecast (B)	44,300	(7,700)	(6,900)	6,200	149.74
Change (B - A)	—	(10,000)	(10,000)	—	
Change rate (%)	—	—	—	—	
(Reference) Results for the previous fiscal year (the six months ended September 30, 2024)	42,466	1,781	2,237	5,249	118.75

(2) Revisions to the Consolidated Financial Results Forecast Figures for the Fiscal Year Ending March 31, 2026 (April 1, 2025 - March 31, 2026)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Basic earnings per share
Previously announced forecast (A)	Million yen 91,500	Million yen 6,000	Million yen 7,400	Million yen 12,300	Yen 297.07
Revised forecast (B)	91,500	(4,000)	(2,600)	12,300	297.07
Change (B - A)	—	(10,000)	(10,000)	—	
Change rate (%)	—	—	—	—	
(Reference) Results for the previous fiscal year (Fiscal year ended March 31, 2025)	88,330	5,773	6,974	11,961	274.21

(3) Reasons for the Revision

The Company has positioned the five-year medium-term management plan Beyond 80, which started in April 2025, as a growth investment period and has established the enhancement of its R&D pipeline through licensing-in as one of its key policies.

In the six months ending September 30, 2025, the Company plans to enter into a new technology licensing agreement that was not incorporated in the initial forecast. By recording the upfront payment from this agreement as R&D expenses, operating profit and ordinary profit for the six months ending September 30, 2025, and for the fiscal year ending March 31, 2026, are each expected to decrease by ¥10,000 million.

However, by recording gain on sale of investment securities as extraordinary income in the six months ending September 30, 2025, profit attributable to owners of parent for the six months ending September 30, 2025 and for the fiscal year ending March 31, 2026 are expected to be ¥6,200 million and ¥12,300 million, respectively, as initially forecasted.

2. Recording of Extraordinary Income

(1) Reasons for the Sale of Investment Securities

The purpose is to improve medium- to long-term return on capital by allocating cash obtained from the sale of investment securities to growth investments, primarily in R&D. The Company is working to improve capital efficiency toward the realization of management that is conscious of the cost of capital and stock price, and this matter is part of such efforts.

(2) Overview of the Sales of Investment Securities

- (i) Shares sold (plan): Two listed stocks held by the Company
- (ii) Period of sale (plan): From July 30, 2025 to September 30, 2025
- (iii) Gain on sale of investment securities (forecast): Approx. ¥12,000 million

(Note) The forecasts above are based on information available to the Company as of the date of publication of this document and certain assumptions as of the date of publication of this document on uncertainties that may affect future financial results. Actual results may differ greatly from these forecasts due to a variety of factors in the future.

-End-